Literature DB >> 9648586

Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma.

T Kurihara1, H Mizunuma, M Obara, K Andoh, Y Ibuki, T Nishimura.   

Abstract

In an attempt to determine a normal level of CA125 in postmenopausal women, CA125 levels of normal postmenopausal women (n = 36, 58.2 +/- 8.1 years) and postmenopausal women undergoing hormone replacement therapy (HRT) (n = 111, 56.8 +/- 6.1 years) were studied. A mean CA125 concentration of 10.0 +/- 3.8 U/ml was found in postmenopausal women without HRT and was significantly lower than that of postmenopausal women undergoing HRT (12.8 +/- 3.8 U/ml), indicating that the cutoff level of CA125 in postmenopausal women or women without reproductive organs should be estimated at a level lower than that conventionally accepted. A receiver operating characteristic (ROC) curve for a preoperative evaluation of myometrial invasion was analyzed in postmenopausal women with endometrial cancer (n = 110). A novel cutoff level of 20 U/ml of CA125 could detect myometrial invasion to more than one-half of the myometrium with sensitivity of 69.0%, specificity of 74.1%, positive predictive value of 58.8%, and negative predictive value of 81.6%. In addition, the distribution of CA125 levels was analyzed in patients who had undergone an operation for endometrial cancer more than 2 years earlier and as yet had no clinical evidence of recurrence of the disease. Ninety-six point two percent of 619 measurement values were lower than 20 U/ml. These results suggest that the novel CA125 level of 20 U/ml is clinically useful for preoperative evaluation and postoperative surveillance of endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648586     DOI: 10.1006/gyno.1998.5018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Authors:  Christine C Johnson; Bruce Kessel; Thomas L Riley; Lawrence R Ragard; Craig R Williams; Jian-Lun Xu; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2008-06-30       Impact factor: 5.482

2.  Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer.

Authors:  Iztok Takac; Borut Gorisek
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

3.  Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.

Authors:  Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

4.  Post-treatment [¹⁸F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma.

Authors:  Hyun Hoon Chung; Jae Weon Kim; Keon Wook Kang; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-14       Impact factor: 9.236

5.  Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.

Authors:  Sandro Sironi; Maria Picchio; Claudio Landoni; Stefania Galimberti; Mauro Signorelli; Valentino Bettinardi; Patrizia Perego; Costantino Mangioni; Cristina Messa; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-16       Impact factor: 9.236

6.  Serum carcinoembryonic antigen as a tumour marker in patients with endometrial cancer.

Authors:  Y Hashiguchi; M Kasai; T Fukuda; T Ichimura; T Yasui; T Sumi
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

7.  Serum Sialyl-Tn (STN) as a Tumor Marker in Patients with Endometrial Cancer.

Authors:  Yasunori Hashiguchi; Mari Kasai; Takeshi Fukuda; Tomoyuki Ichimura; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Pathol Oncol Res       Date:  2015-12-17       Impact factor: 3.201

8.  Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Woo Young Kim; Suk-Joon Chang; Hee-Jae Joo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

9.  The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

10.  Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial.

Authors:  V Seebacher; S Polterauer; C Grimm; J Rahhal; G Hofstetter; E-M Bauer; H Husslein; H Leipold; C Marth; A Reinthaller; N Concin
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.